Study of felzartamab for adults with primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary membranous nephropathy and your doctor thinks you need treatment to suppress your immune system.
- You have either just been diagnosed and never had immune-suppressing treatment, or you had such treatment in the past and your protein in the urine came back after a remission.
- You are taking a blood pressure medicine called an ACE inhibitor or ARB (or a similar drug) at a full or maximum tolerated dose for at least 4 weeks before the study starts, unless you cannot tolerate it.
- Your urine test shows a high level of protein (UPCR ≥ 3.0 or ≥ 3.5 grams per day) despite this treatment.
- You do not have another cause for your kidney disease, such as certain cancers, infections, or lupus.
- Your kidney function is not severely reduced (eGFR more than 30 mL/min/1.73m²) and you are not on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new drug called telitacicept in people with primary membranous nephropathy, a kidney condition that causes protein leakage in urine. It aims to see if the drug can reduce protein loss and protect kidney function, potentially slowing the disease's progression.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.